Lentivirus for treating craniopharyngeal tubuloma as well as preparation method and application of lentivirus
By using lentiviruses carrying the hTERT promoter and CDC6shRNA genes, the treatment gene is transmitted to craniopharyngioma cells, solving the problem that existing treatment methods cannot effectively inhibit tumor growth, and achieving safe and effective gene therapy effects.
CN119709646APending Publication Date: 2025-03-28QINGDAO ARTAI GENE CO LTD
3 Cites 1 Cited by
Patent Information
- Application Number
- CN202411296490.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
Existing treatment methods for cranopharyngioma, such as surgery, radiation therapy and drug therapy, have not been effective in inhibiting tumor growth, and there is a high risk of postoperative complications and recurrence rates.
Method used
The purpose of gene therapy is achieved by using lentiviruses carrying the hTERT promoter and CDC6shRNA genes.
Benefits of technology
This method can effectively inhibit the proliferation of craniopharyngioma cells and induce self-apoptotics, providing a safe and effective treatment plan, significantly reducing the tumor volume, and no adverse reactions occurred during the treatment process.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention provides a lentivirus for treating craniopharyngeal tubuloma as well as a preparation method, application and a corresponding pharmaceutical composition of the lentivirus. The lentivirus carries an hTERT (human telomerase reverse transcriptase) promoter and a CDC6shRNA (complementary deoxyribonucleic acid) gene. According to the invention, an hTERT promoter and a CDC6shRNA gene sequence are inserted behind an enzyme cutting site of a vector, an obtained plasmid is transferred into an expression strain, the expression strain is cultured and screened to obtain a cloned strain, and the cloned strain is shaken and packaged to obtain the hTERT-CDC6shRNA lentivirus; when the lentivirus disclosed by the invention is inoculated into a tumor body of a patient with craniopharyngeal tubuloma, the result shows that the lentivirus can effectively inhibit proliferation of craniopharyngeal tubuloma cells and can induce self apoptosis of the craniopharyngeal tubuloma cells.
Need to check novelty before this filing date? Find Prior Art